XML 38 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
Description of Business and Summary of Significant Accounting Policies (Details Textual)
 1 Months Ended 3 Months Ended
Feb. 28, 2017
Mar. 31, 2017
Description of Business and Summary of Significant Accounting Policies (Textual)    
Dose escalation study description Patients will be administered Actimab-M on day 1 at an initial dose of 0.5 µCi/kg and then assessed at day 42 for safety and efficacy. The dose can be increased to 1.0 µCi/kg or reduced to 0.25 µCi/kg based on safety assessment that will evaluate dose limiting toxicities (DLTs). Patients may receive up to 8 cycles of therapy but in no event will cumulative administration exceed 4.0 µCi/kg of Actimab-M.  
Machinery and equipment [Member]    
Description of Business and Summary of Significant Accounting Policies (Textual)    
Estimated useful lives   Three years
Property and equipment depreciation method   Straight-line basis
Furniture and fixtures [Member]    
Description of Business and Summary of Significant Accounting Policies (Textual)    
Estimated useful lives   Three years
Property and equipment depreciation method   Straight-line basis